1. Home
  2. CIK vs BMEA Comparison

CIK vs BMEA Comparison

Compare CIK & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Credit Suisse Asset Management Income Fund Inc.

CIK

Credit Suisse Asset Management Income Fund Inc.

HOLD

Current Price

$2.58

Market Cap

136.1M

Sector

Finance

ML Signal

HOLD

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.37

Market Cap

138.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CIK
BMEA
Founded
N/A
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
136.1M
138.1M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
CIK
BMEA
Price
$2.58
$1.37
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$9.83
AVG Volume (30 Days)
477.7K
1.9M
Earning Date
01-01-0001
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
69.19
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.44
$0.87
52 Week High
$3.01
$3.07

Technical Indicators

Market Signals
Indicator
CIK
BMEA
Relative Strength Index (RSI) 47.91 37.80
Support Level $2.44 $1.15
Resistance Level $3.00 $1.47
Average True Range (ATR) 0.03 0.15
MACD 0.00 -0.09
Stochastic Oscillator 45.00 4.90

Price Performance

Historical Comparison
CIK
BMEA

About CIK Credit Suisse Asset Management Income Fund Inc.

Credit Suisse Asset Mgmt Income Fund Inc is a closed-end management investment company. The investment objective of the fund is to provide current income consistent with the preservation of capital. UBS Asset Management serves as an investment adviser for the fund. Asset Management offers a wide range of investment products and functions across asset classes and investment styles. The division manages various regional portfolios, mutual funds, and other investment vehicles for governments, institutions, corporations and individuals.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

Share on Social Networks: